Analytical Data
-
基因名
LIV-1/SLC39A6
-
简介
LIV-1/SLC39A6 is a zinc influx transporter that regulates zinc homeostasis and induces epithelial-mesenchymal transition (EMT). Used in conjunction with SLC39A10, it can promote cellular zinc absorption and trigger EMT. LIV-1/SLC39A6 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is the recombinant cynomolgus-derived LIV-1/SLC39A6 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
- Application
-
别名
SLC39A6; LIV-1; ZIP6; Zinc transporter ZIP6; ZIP-6
-
种属
Cynomolgus
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
XP_005586923
-
表达区间
L21-I309
-
分子量
50-65 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LIV-1, also known as SLC39A6, is a member of the solute carrier family of transporters that plays a crucial role in cellular zinc homeostasis. Zinc is an essential trace element required for numerous biological processes, including enzyme function, cellular signaling, and immune response. Abnormal zinc transport has been linked to various diseases, including cancers and neurodegenerative disorders. LIV-1 is particularly notable for its involvement in breast cancer, where it has been associated with tumor progression and metastasis. Research has shown that LIV-1 expression is elevated in certain breast cancer subtypes, making it a potential target for therapeutic interventions. The study of LIV-1/SLC39A6 recombinant protein is crucial for understanding its structure-function relationship and elucidating its role in zinc transport. By generating and characterizing recombinant LIV-1, researchers aim to explore its mechanism of action, identify potential inhibitors, and ultimately pave the way for new strategies in cancer treatment and prevention. Understanding how LIV-1 interacts with zinc and other cellular components could also provide insights into broader physiological and pathological processes, enhancing our knowledge of zinc transporter networks and their implications in health and disease.
